Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $262.6 million.

  • Ani Pharmaceuticals' Cash & Current Investments rose 8111.39% to $262.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.6 million, marking a year-over-year increase of 8111.39%. This contributed to the annual value of $144.9 million for FY2024, which is 3447.3% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Cash & Current Investments stood at $262.6 million for Q3 2025, which was up 8111.39% from $217.8 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Cash & Current Investments registered a high of $262.6 million during Q3 2025, and its lowest value of $15.3 million during Q3 2021.
  • In the last 5 years, Ani Pharmaceuticals' Cash & Current Investments had a median value of $144.9 million in 2024 and averaged $129.9 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Cash & Current Investments skyrocketed by 71838.04% in 2021, and later crashed by 4944.59% in 2022.
  • Ani Pharmaceuticals' Cash & Current Investments (Quarter) stood at $105.3 million in 2021, then crashed by 49.45% to $53.2 million in 2022, then surged by 315.38% to $221.1 million in 2023, then tumbled by 34.47% to $144.9 million in 2024, then skyrocketed by 81.27% to $262.6 million in 2025.
  • Its Cash & Current Investments stands at $262.6 million for Q3 2025, versus $217.8 million for Q2 2025 and $149.8 million for Q1 2025.